XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions - Narrative (Details)
₩ in Billions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 27, 2020
USD ($)
shares
Aug. 27, 2020
KRW (₩)
shares
Nov. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Jan. 31, 2016
May 31, 2015
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
USD ($)
Mar. 31, 2014
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2010
USD ($)
Feb. 20, 2020
shares
Dec. 31, 2019
USD ($)
Related-Party Transactions (Textual) [Abstract]                            
Proceeds from issuance of stock                   $ 329,960,855 $ 3,425,065      
Revenue from related parties             $ 236,178 $ 866,863   1,830,639 3,832,442      
GeneOne Life Sciences                            
Related-Party Transactions (Textual) [Abstract]                            
Number of shares issued in transaction (in shares) | shares 1,644,155 1,644,155                        
Proceeds from issuance of stock $ 40,100,000 ₩ 47.4                        
Accounts receivable 128,000                          
Accounts payable/accrued liabilities $ 511,000                          
Payment received for license granted                       $ 3,000,000.0    
Term                 20 years          
Milestone-based ownership target         35.00% 35.00%                
Revenue from related parties             94,000 94,000   31,000 31,000      
Operating expenses related to affiliated entity             1,600,000 232,000   4,400,000 2,100,000      
Plumbline Life Sciences                            
Related-Party Transactions (Textual) [Abstract]                            
Accounts receivable             40,000     40,000       $ 589,000
Revenue from related parties             $ 83,000 22,000   $ 1,300,000 86,000      
Plumbline Life Sciences | Available-for-sale Securities                            
Related-Party Transactions (Textual) [Abstract]                            
Investment owned (in shares) | shares             597,808     597,808        
Investment owned, additional shares acquired (in shares) | shares                         202,050  
Director                            
Related-Party Transactions (Textual) [Abstract]                            
Accounts receivable             $ 443,000     $ 443,000       616,000
Accounts payable/accrued liabilities             795,000     795,000       $ 219,000
Term       5 years                    
Operating expenses related to affiliated entity             411,000 313,000   1,200,000 1,100,000      
Expenses to reimburse       $ 3,100,000                    
Awarded amount     $ 6,100,000                      
Contra-research and development expense             1,000,000.0 $ 482,000   1,700,000 $ 1,700,000      
Deferred grant funding, from affiliate             $ 173,000     $ 173,000        
Plumbline Life Sciences                            
Related-Party Transactions (Textual) [Abstract]                            
Ownership percentage             19.90%     19.90%